HK1187207A1 - Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors s- - Google Patents
Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors s-Info
- Publication number
- HK1187207A1 HK1187207A1 HK14100371.3A HK14100371A HK1187207A1 HK 1187207 A1 HK1187207 A1 HK 1187207A1 HK 14100371 A HK14100371 A HK 14100371A HK 1187207 A1 HK1187207 A1 HK 1187207A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- reductase inhibitors
- novel substituted
- substituted quinoline
- quinoline compounds
- nitrosoglutathione reductase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39122510P | 2010-10-08 | 2010-10-08 | |
US42380510P | 2010-12-16 | 2010-12-16 | |
PCT/US2011/055200 WO2012048181A1 (en) | 2010-10-08 | 2011-10-07 | Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1187207A1 true HK1187207A1 (en) | 2014-04-04 |
Family
ID=45928135
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14100371.3A HK1187207A1 (en) | 2010-10-08 | 2014-01-13 | Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors s- |
HK16103862.1A HK1215862A1 (zh) | 2010-10-08 | 2016-04-06 | 作爲 -亞硝基谷胱甘肽還原酶抑制劑的新的取代喹啉化合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16103862.1A HK1215862A1 (zh) | 2010-10-08 | 2016-04-06 | 作爲 -亞硝基谷胱甘肽還原酶抑制劑的新的取代喹啉化合物 |
Country Status (23)
Country | Link |
---|---|
US (5) | US8921562B2 (de) |
EP (2) | EP2624695B1 (de) |
JP (2) | JP5855113B2 (de) |
KR (1) | KR101886459B1 (de) |
CN (1) | CN103200820B (de) |
AU (1) | AU2011311920B2 (de) |
BR (1) | BR112013007907A2 (de) |
CA (1) | CA2811791C (de) |
DK (1) | DK2624695T3 (de) |
ES (1) | ES2553771T3 (de) |
HK (2) | HK1187207A1 (de) |
HR (1) | HRP20151405T1 (de) |
HU (1) | HUE025653T2 (de) |
IL (1) | IL223829A (de) |
IN (1) | IN2013MN00501A (de) |
PL (1) | PL2624695T3 (de) |
PT (1) | PT2624695E (de) |
RS (1) | RS54369B1 (de) |
RU (1) | RU2599144C2 (de) |
SI (1) | SI2624695T1 (de) |
SM (1) | SMT201600021B (de) |
WO (1) | WO2012048181A1 (de) |
ZA (1) | ZA201303257B (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012048181A1 (en) | 2010-10-08 | 2012-04-12 | N30 Pharmaceuticals, Llc | Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors |
CA2821412A1 (en) | 2010-12-16 | 2012-06-21 | N30 Pharmaceuticals, Inc. | Novel substituted bicyclic aromatic compounds as s-nitrosoglutathione reductase inhibitors |
US20140094465A1 (en) * | 2011-06-10 | 2014-04-03 | N30 Pharmaceuticals, Inc. | Compounds as S-Nitrosoglutathione Reductase Inhibitors |
EP3204010A1 (de) * | 2014-10-08 | 2017-08-16 | Nivalis Therapeutics, Inc. | Verfahren zur behandlung von zystischer fibrose |
CN104496998B (zh) * | 2014-12-15 | 2017-07-11 | 陕西嘉禾生物科技股份有限公司 | 一种1′‑苄基‑2′‑酮‑5′,7′,8′‑三氢‑螺‑[1,3‑二氧五环‑2]‑喹啉的制备方法 |
WO2016128905A1 (en) * | 2015-02-10 | 2016-08-18 | Glenmark Pharmaceuticals S.A. | Thienopyrrole compounds as s-nitrosoglutathione reductase inhibitors |
US9840513B2 (en) | 2015-07-16 | 2017-12-12 | Abbvie S.Á.R.L. | Substituted tricyclics and method of use |
US10399946B2 (en) | 2015-09-10 | 2019-09-03 | Laurel Therapeutics Ltd. | Solid forms of an S-Nitrosoglutathione reductase inhibitor |
WO2017044788A1 (en) * | 2015-09-10 | 2017-03-16 | Nivalis Therapeutics, Inc. | Formulations of an s-nitrosoglutathione reductase inhibitor |
WO2017062611A1 (en) * | 2015-10-07 | 2017-04-13 | Nivalis Therapeutics, Inc. | Methods for the treatment of cystic fibrosis |
EP3359540A1 (de) | 2015-10-09 | 2018-08-15 | AbbVie S.À.R.L. | Neuartige verbindungen zur behandlung von zystischer fibrose |
TW201735769A (zh) | 2015-10-09 | 2017-10-16 | 盧森堡商艾伯維公司 | 經取代之吡唑并[3,4-b]吡啶-6-羧酸及使用方法 |
SI3359541T1 (sl) | 2015-10-09 | 2021-01-29 | Abbvie Overseas S.A R.L. | N-sulfonirani pirazolo(3,4 b)piridin-6-karboksamidi in postopki uporabe |
WO2017151725A1 (en) * | 2016-03-03 | 2017-09-08 | Nivalis Therapeutics, Inc. | Formulations of an s-nitrosoglutathione reductase inhibitor |
BR112018072047A2 (pt) | 2016-04-26 | 2019-02-12 | AbbVie S.à.r.l. | moduladores da proteína reguladora de condutância transmembranar de fibrose cística |
US10138227B2 (en) | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
US10399940B2 (en) | 2016-10-07 | 2019-09-03 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
US9981910B2 (en) | 2016-10-07 | 2018-05-29 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
US20200123137A1 (en) | 2016-12-20 | 2020-04-23 | AbbVie S.à.r.l. | Deuterated cftr modulators and methods of use |
TW201831471A (zh) | 2017-02-24 | 2018-09-01 | 盧森堡商艾伯維公司 | 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法 |
US10988454B2 (en) | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
WO2019193062A1 (en) | 2018-04-03 | 2019-10-10 | Abbvie S.Á.R.L | Substituted pyrrolidines and their use |
CN108794395B (zh) * | 2018-07-06 | 2021-04-20 | 大连理工大学 | 一种2-喹啉酮类化合物的制备方法 |
US11345691B2 (en) | 2019-06-03 | 2022-05-31 | AbbVie Global Enterprises Ltd. | Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
WO2021011327A1 (en) | 2019-07-12 | 2021-01-21 | Orphomed, Inc. | Compound for treating cystic fibrosis |
WO2021217028A1 (en) * | 2020-04-23 | 2021-10-28 | University Hospitals - Cleveland Medical Center | Compositions and methods for in vivo lung and blood sno repletion |
EP4274828A1 (de) | 2021-01-06 | 2023-11-15 | AbbVie Global Enterprises Ltd. | Modulatoren des regulatorproteins der transmembran-leitfähigkeit zystischer fibrose und verfahren zur verwendung |
WO2022150173A1 (en) | 2021-01-06 | 2022-07-14 | AbbVie Global Enterprises Ltd. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4431440A (en) | 1981-02-20 | 1984-02-14 | American Cyanamid Company | Method to alter or control the development and/or the life cycle of various plant species |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
DE19517038A1 (de) | 1995-05-10 | 1996-11-14 | Hoechst Ag | 1,8-Difluorisochinolinderivate und ihre Verwendung in flüssigkristallinen Mischungen |
DE19517060A1 (de) | 1995-05-10 | 1996-11-14 | Hoechst Ag | 1-Fluorisochinolinderivate und ihre Verwendung in flüssigkristallinen Mischungen |
JP2000514048A (ja) | 1996-06-20 | 2000-10-24 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | 薬理学的活性調製物を提供するための化合物および方法ならびにそれらの使用 |
US6057367A (en) | 1996-08-30 | 2000-05-02 | Duke University | Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses |
US6180632B1 (en) | 1997-05-28 | 2001-01-30 | Aventis Pharmaceuticals Products Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
CA2291750A1 (en) | 1997-05-28 | 1998-12-03 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
ATE413386T1 (de) | 1998-01-29 | 2008-11-15 | Amgen Inc | Ppar-gamma modulatoren |
EP1171814A1 (de) | 1999-03-30 | 2002-01-16 | BRITISH TELECOMMUNICATIONS public limited company | Netzwerk druckverfahren und -gerät |
AU5261001A (en) | 2000-04-27 | 2001-11-12 | Imperial Cancer Research Technology Ltd | Condensed heteroaryl derivatives |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
CA2424300A1 (en) | 2000-10-02 | 2002-04-11 | Molecular Probes, Inc. | Reagents for labeling biomolecules having aldehyde or ketone moieties |
US6359182B1 (en) | 2000-10-26 | 2002-03-19 | Duke University | C-nitroso compounds and use thereof |
US7049308B2 (en) | 2000-10-26 | 2006-05-23 | Duke University | C-nitroso compounds and use thereof |
US7179791B2 (en) | 2001-01-11 | 2007-02-20 | Duke University | Inhibiting GS-FDH to modulate NO bioactivity |
JP2002226464A (ja) | 2001-01-30 | 2002-08-14 | Sumitomo Pharmaceut Co Ltd | トリアリール類縁体およびその利用 |
RU2347570C2 (ru) * | 2001-07-02 | 2009-02-27 | Н.В.Органон | Тетрагидрохинолиновые производные |
US7173128B2 (en) | 2001-08-13 | 2007-02-06 | Ciba Specialty Chemicals Corporation | Ultraviolet light absorbers |
AT500490A1 (de) | 2001-10-16 | 2006-01-15 | Dsm Fine Chem Austria Gmbh | Verfahren zur herstellung von substituierten thiazolinen und deren zwischenprodukte |
JPWO2004035522A1 (ja) | 2002-08-30 | 2006-02-16 | 株式会社 ビーエフ研究所 | プリオン蛋白蓄積性疾患の診断プローブおよび治療薬ならびにプリオン蛋白の染色剤 |
US7118730B2 (en) | 2002-12-16 | 2006-10-10 | Bf Research Institute, Inc. | Quinoline derivative as diagnostic probe for disease with tau protein accumulation |
US20060166984A1 (en) | 2003-03-10 | 2006-07-27 | Gerd Steiner | Amino substituted benzo(hetero)cyclic derivatives |
CL2004000985A1 (es) | 2003-05-16 | 2005-01-14 | Wyeth Corp | Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc |
US20050014697A1 (en) | 2003-06-04 | 2005-01-20 | Stamler Jonathan S. | Compositions and methods for modulating S-nitrosoglutathione reductase |
AU2003304416A1 (en) | 2003-08-13 | 2005-03-07 | Bf Research Institute, Inc. | Probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change |
JP2007516289A (ja) | 2003-12-23 | 2007-06-21 | ミオゲン インコーポレイティッド | 心血管および筋疾患治療のための5−ht2受容体調節物質、それらの薬学的組成物およびそれらの使用 |
ITTO20040125A1 (it) | 2004-03-01 | 2004-06-01 | Rotta Research Lab | Nuove amidine eterocicliche inibitrici la produzione di ossido d'azoto (no) ad attivita' antinfiammatoria ed analgesica |
WO2005118580A2 (en) | 2004-05-12 | 2005-12-15 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health | Tricyclic compounds as inhibitors of the hypoxic signaling pathway |
WO2006004722A2 (en) | 2004-06-30 | 2006-01-12 | Biomol Research Laboratories, Inc. | Compositions and methods for selectively activating human sirtuins |
WO2006034491A2 (en) * | 2004-09-23 | 2006-03-30 | Bayer Pharmaceuticals Corporation | Phenyl-substituted quinoline and quinazoline compounds for the treatment of diabetes |
SE0402925D0 (sv) * | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
CN101068551A (zh) * | 2004-12-03 | 2007-11-07 | 默克公司 | 喹啉速激肽受体拮抗剂 |
EP1683523A1 (de) | 2005-01-25 | 2006-07-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | 2-phenylchinoxaline als mpp1 inhibitoren |
US7683066B2 (en) | 2005-05-20 | 2010-03-23 | Vertex Pharmaceuticals Incorporated | Isoquinolines useful as modulators of ion channels |
EP2778234B1 (de) * | 2005-05-31 | 2017-09-27 | Promega Corporation | Luminogene und fluorogene verbindungen und verfahren für den nachweis von molekülen oder leiden |
MX2007015679A (es) | 2005-06-30 | 2008-02-21 | Amgen Inc | Inhibidores de quinasa bis-aril y su uso en el tratamiento de inflamacion, angiogenesis y cancer. |
NZ566180A (en) * | 2005-07-29 | 2011-04-29 | Resverlogix Corp | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
GB0618168D0 (en) | 2006-09-15 | 2006-10-25 | Babraham Inst | Compounds |
KR101299233B1 (ko) | 2006-10-31 | 2013-08-22 | 삼성디스플레이 주식회사 | 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자 |
AU2007328336B2 (en) | 2006-12-01 | 2014-04-17 | President And Fellows Of Harvard College | Compounds and methods for enzyme-mediated tumor imaging and therapy |
WO2009008906A2 (en) | 2007-02-06 | 2009-01-15 | The Trustees Of The University Of Pennsylvania | Therapeutic compounds for blocking dna synthesis of pox viruses |
DE102007015169A1 (de) * | 2007-03-27 | 2008-10-02 | Universität des Saarlandes Campus Saarbrücken | 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
BRPI0701664A2 (pt) | 2007-05-28 | 2009-01-13 | Fundacao Universidade Fed De Sco Carlos | 4-quinolinonas e quinolinas, processo de preparaÇço, formulaÇÕes farmacÊuticas e uso das mesmas |
WO2008157500A1 (en) | 2007-06-17 | 2008-12-24 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
EP2014651A1 (de) | 2007-07-12 | 2009-01-14 | Exonhit Therapeutics SA | Verbindungen und Verfahren zur Modulierung von Rho-GTPasen |
EP2581451B1 (de) | 2007-12-13 | 2016-03-09 | Indiana University Research and Technology Corporation | Verbindungen zur Hemmung der S-Nitrosoglutathionreduktase bei Säugetieren |
US20100144733A1 (en) | 2008-04-28 | 2010-06-10 | Institute For Oneworld Health | Compounds, compositions and methods comprising heteroaromatic derivatives |
US8466290B2 (en) * | 2008-07-10 | 2013-06-18 | Pharma Ip General Incorporated Association | STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient |
WO2010018458A2 (en) | 2008-08-12 | 2010-02-18 | Crystalgenomics, Inc. | Phenol derivatives and methods of use thereof |
DK2315590T3 (da) * | 2008-08-15 | 2012-11-19 | N30 Pharmaceuticals Inc | Pyrrolinhibitorer af S-nitrosoglutathionreduktase |
EP2318007B1 (de) | 2008-08-15 | 2013-01-23 | N30 Pharmaceuticals, Inc. | Neuartige pyrrolhemmer der s-nitrosoglutathion-reduktase als therapeutische mittel |
EP3069721A1 (de) * | 2008-08-15 | 2016-09-21 | Nivalis Therapeutics, Inc. | Neuartige pyrrolhemmer der s-nitrosoglutathion-reduktase als therapeutische mittel |
CA2739060C (en) * | 2008-10-15 | 2016-08-23 | Kissei Pharmaceutical Co., Ltd. | Fused-ring derivative and medical application of same |
SI2349263T1 (sl) | 2008-10-23 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Modulatorji cistiäśno-fibroznega transmembranskega regulatorja prevodnosti |
WO2010107476A1 (en) | 2009-03-19 | 2010-09-23 | Duke University | Inhibiting gsnor |
MX2012006615A (es) | 2009-12-11 | 2012-10-05 | Autifony Therapeuticts Ltd | Derivados de imidazolidinodiona. |
AU2011215833B2 (en) | 2010-02-12 | 2015-07-09 | Nivalis Therapeutics, Inc. | Novel S-nitrosoglutathione reductase inhibitors |
WO2012048181A1 (en) | 2010-10-08 | 2012-04-12 | N30 Pharmaceuticals, Llc | Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors |
CA2821412A1 (en) | 2010-12-16 | 2012-06-21 | N30 Pharmaceuticals, Inc. | Novel substituted bicyclic aromatic compounds as s-nitrosoglutathione reductase inhibitors |
US20140094465A1 (en) | 2011-06-10 | 2014-04-03 | N30 Pharmaceuticals, Inc. | Compounds as S-Nitrosoglutathione Reductase Inhibitors |
-
2011
- 2011-10-07 WO PCT/US2011/055200 patent/WO2012048181A1/en active Application Filing
- 2011-10-07 RU RU2013112122/04A patent/RU2599144C2/ru active IP Right Revival
- 2011-10-07 PT PT118316512T patent/PT2624695E/pt unknown
- 2011-10-07 KR KR1020137010664A patent/KR101886459B1/ko active IP Right Grant
- 2011-10-07 AU AU2011311920A patent/AU2011311920B2/en not_active Ceased
- 2011-10-07 HU HUE11831651A patent/HUE025653T2/hu unknown
- 2011-10-07 EP EP11831651.2A patent/EP2624695B1/de active Active
- 2011-10-07 US US13/824,430 patent/US8921562B2/en active Active
- 2011-10-07 CA CA2811791A patent/CA2811791C/en not_active Expired - Fee Related
- 2011-10-07 DK DK11831651.2T patent/DK2624695T3/en active
- 2011-10-07 ES ES11831651.2T patent/ES2553771T3/es active Active
- 2011-10-07 JP JP2013532965A patent/JP5855113B2/ja not_active Expired - Fee Related
- 2011-10-07 BR BR112013007907A patent/BR112013007907A2/pt not_active Application Discontinuation
- 2011-10-07 PL PL11831651T patent/PL2624695T3/pl unknown
- 2011-10-07 SI SI201130672T patent/SI2624695T1/sl unknown
- 2011-10-07 EP EP15180449.9A patent/EP2977050A1/de not_active Withdrawn
- 2011-10-07 CN CN201180052350.7A patent/CN103200820B/zh active Active
- 2011-10-07 RS RS20150786A patent/RS54369B1/en unknown
- 2011-10-07 IN IN501MUN2013 patent/IN2013MN00501A/en unknown
-
2012
- 2012-12-24 IL IL223829A patent/IL223829A/en not_active IP Right Cessation
-
2013
- 2013-05-06 ZA ZA2013/03257A patent/ZA201303257B/en unknown
-
2014
- 2014-01-13 HK HK14100371.3A patent/HK1187207A1/xx not_active IP Right Cessation
- 2014-11-13 US US14/540,216 patent/US9139528B2/en not_active Expired - Fee Related
-
2015
- 2015-08-04 US US14/817,329 patent/US9315462B2/en not_active Expired - Fee Related
- 2015-10-19 JP JP2015205282A patent/JP2016074667A/ja active Pending
- 2015-12-21 HR HRP20151405TT patent/HRP20151405T1/hr unknown
-
2016
- 2016-01-21 SM SM201600021T patent/SMT201600021B/it unknown
- 2016-04-06 HK HK16103862.1A patent/HK1215862A1/zh unknown
- 2016-04-13 US US15/097,378 patent/US9433618B2/en active Active
- 2016-08-04 US US15/228,088 patent/US9856219B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1215862A1 (zh) | 作爲 -亞硝基谷胱甘肽還原酶抑制劑的新的取代喹啉化合物 | |
HK1178742A1 (zh) | -亞硝基谷胱甘肽還原酶的新抑制劑 | |
ZA201309561B (en) | Novel inhibitor compounds of phosphodiestarase type 10a | |
HK1187259A1 (zh) | 取代的喹啉化合物 | |
ZA201306221B (en) | Compounds and compositions as trk inhibitors | |
SI2563771T1 (sl) | Spojine inhibitorjev metaloencimov | |
EP2552208A4 (de) | Imidazolyl-imidazole als kinasehemmer | |
GB201004311D0 (en) | New enzyme inhibitor compounds | |
EP2552214A4 (de) | Pyrazolyl-pyrimidine als kinasehemmer | |
EP2552211A4 (de) | Indazolyl-pyrimidine als kinasehemmer | |
AP3529A (en) | Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors | |
EP2638021A4 (de) | Metalloenzymhemmerverbindungen | |
EP2651871A4 (de) | Neue substituierte bicyclische aromatische verbindungen als s-nitrosoglutathion-reduktasehemmer | |
EP2480086A4 (de) | Neue dihydropyrimidin-2(1h)-on-verbindungen als s-nitrosoglutathion-reduktasehemmer | |
ZA201206456B (en) | Uses of dgati inhibitors | |
HK1184451A1 (en) | 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors 4--2--1--4- | |
ZA201208363B (en) | Novel intermediates for the preparation of hmg-coa reductase inhibitors | |
EP2632903A4 (de) | Metalloenzymhemmerverbindungen | |
EP2533637A4 (de) | Chromonhemmer der s-nitrosoglutathion-reduktase | |
EP2651905A4 (de) | Metalloenzymhemmerverbindungen | |
HK1191327A1 (en) | Azaspirodecanone compounds as hsl inhibitors hsl | |
GB201113689D0 (en) | Novel PDE4 inhibitors | |
ZA201502878B (en) | Novel benzyl sulfonamide compounds useful as mogat-2 inhibitors | |
GB201006605D0 (en) | Novel inhibitors | |
GB201003936D0 (en) | Novel inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20221009 |